天譽置業(00059.HK)附屬競得廣州黃埔商品房合作項目
天譽置業(00059.HK)公布,於12月21日,間接全資附屬天譽巨榮接獲廣州市黃埔區九佛街鳳尾村經濟聯合社通知,經過廣州公共資源交易中心招標公開引入合作企業的程序及得出的結果,同意天譽巨榮為項目的競得合作企業,並將按照招商文件和競選文件的約定簽署相關合作協議。
項目位於廣州市黃埔區九佛街鳳尾村,東至開放大道,南至康耀七路,西至永九快速,北至康耀北路。項目毗鄰地鐵紅衛站,距離廣州市中心天河區地鐵車程約一小時,並臨近國際生物醫藥創新園。項目預估商品房計容建築面積約76.3萬平方米,最終建築面積以屆時報建時主管機構最終批復為准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.